AU2011310664B2 - Compositions and methods for treating neoplasia - Google Patents

Compositions and methods for treating neoplasia Download PDF

Info

Publication number
AU2011310664B2
AU2011310664B2 AU2011310664A AU2011310664A AU2011310664B2 AU 2011310664 B2 AU2011310664 B2 AU 2011310664B2 AU 2011310664 A AU2011310664 A AU 2011310664A AU 2011310664 A AU2011310664 A AU 2011310664A AU 2011310664 B2 AU2011310664 B2 AU 2011310664B2
Authority
AU
Australia
Prior art keywords
antibody
cell
chimeric antibody
chimeric
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011310664A
Other languages
English (en)
Other versions
AU2011310664A1 (en
Inventor
Avgi Mamalaki
Evangelia Patsavoudi
Katerina Sidera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZESTAGEN SA
Original Assignee
Zestagen S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zestagen S A filed Critical Zestagen S A
Publication of AU2011310664A1 publication Critical patent/AU2011310664A1/en
Application granted granted Critical
Publication of AU2011310664B2 publication Critical patent/AU2011310664B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2011310664A 2010-09-27 2011-09-27 Compositions and methods for treating neoplasia Ceased AU2011310664B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38676410P 2010-09-27 2010-09-27
US61/386,764 2010-09-27
PCT/EP2011/066791 WO2012041863A1 (en) 2010-09-27 2011-09-27 Compositions and methods for treating neoplasia

Publications (2)

Publication Number Publication Date
AU2011310664A1 AU2011310664A1 (en) 2013-05-09
AU2011310664B2 true AU2011310664B2 (en) 2016-02-18

Family

ID=44675608

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011310664A Ceased AU2011310664B2 (en) 2010-09-27 2011-09-27 Compositions and methods for treating neoplasia

Country Status (12)

Country Link
US (2) US9115192B2 (https=)
EP (1) EP2621947A1 (https=)
JP (1) JP5946459B2 (https=)
KR (1) KR20140016240A (https=)
CN (1) CN103459420B (https=)
AU (1) AU2011310664B2 (https=)
BR (1) BR112013007327A2 (https=)
CA (1) CA2812644A1 (https=)
IL (1) IL225483A0 (https=)
MX (1) MX2013003561A (https=)
SG (1) SG189095A1 (https=)
WO (1) WO2012041863A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
JP6488520B2 (ja) * 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
TWI728975B (zh) * 2015-05-12 2021-06-01 英屬維爾京群島商遠東超級實驗室有限公司 鑒定對腫瘤具有直接抑制作用的干擾素的方法及其用途
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
US7780963B2 (en) * 2004-10-25 2010-08-24 Merck & Co., Inc. Anti-ADDL antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SIDERA K. et al, A Critical Role for HSP90 in Cancer Cell Invasion Involves Interaction with the Extracellular Domain of HER-2, The Journal of Biological Chemistry, 2008, Vol. 283(4), pg. 2031-2041 *
STELLAS D. et al, Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits, BMC Cell Biology, 2010, Vol. 11(51) *

Also Published As

Publication number Publication date
CA2812644A1 (en) 2012-04-05
WO2012041863A1 (en) 2012-04-05
EP2621947A1 (en) 2013-08-07
US20130280244A1 (en) 2013-10-24
JP2013541944A (ja) 2013-11-21
AU2011310664A1 (en) 2013-05-09
CN103459420B (zh) 2016-09-28
IL225483A0 (en) 2013-06-27
US9115192B2 (en) 2015-08-25
BR112013007327A2 (pt) 2017-07-04
MX2013003561A (es) 2013-09-02
KR20140016240A (ko) 2014-02-07
US20160075771A1 (en) 2016-03-17
SG189095A1 (en) 2013-05-31
JP5946459B2 (ja) 2016-07-06
US9328161B2 (en) 2016-05-03
CN103459420A (zh) 2013-12-18

Similar Documents

Publication Publication Date Title
AU2011310664B2 (en) Compositions and methods for treating neoplasia
JP7220161B2 (ja) 抗ＣＤ４７ｘ抗メソテリン抗体およびそれを使用する方法
CN113544156B (zh) 抗Claudin18.2抗体及其应用
US11359021B2 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CA2597717C (en) Antibodies against cxcr4 and methods of use thereof
KR101960004B1 (ko) Cldn6 생체내 표적-지향된 항체를 이용하는 암 치료법
JP2020526478A6 (ja) 抗ＣＤ４７ｘ抗メソテリン抗体およびそれを使用する方法
AU2016203575A1 (en) Novel anti-DR5 antibody
KR20150013935A (ko) 트랜스포터에 대한 항체 및 이의 용도
CA2954859A1 (en) Anti-mucin 1 binding agents and uses thereof
CN113906053B (zh) 抗cea抗体及其应用
CN117043183A (zh) Tau结合化合物
CN113260632A (zh) 包含IgA抗体构建体的组合物和方法
CN111201031A (zh) 抗CD47 x抗间皮素抗体及其使用方法
WO2025114357A1 (en) Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
WO2026082966A1 (en) Methods of treating disease using anti-cd47 x anti-mesothelin antibodies in combination with chemotherapy
CA2961374A1 (en) Treatment of fibrotic diseases
HK40121102A (zh) 识别tau的抗体
HK40083120B (zh) 抗补体因子c1q的fab片段及其应用
HK40104165A (zh) 抗tau抗体及其用途
HK40059443A (en) Compositions and methods comprising iga antibody constructs
HK1181316B (en) Notch1 binding agents and methods of use thereof
HK1181316A1 (en) Notch1 binding agents and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired